Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 226

1.

Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial.

Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; PRISMA Study Group.

Diabetes Care. 2013 Oct;36(10):2887-94. doi: 10.2337/dc13-0092. Epub 2013 Jun 4.

2.

Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.

Daniels LB, Grady D, Mosca L, Collins P, Mitlak BH, Amewou-Atisso MG, Wenger NK, Barrett-Connor E; Raloxifene Use for the Heart (RUTH) Trial Investigators.

Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):164-70. doi: 10.1161/CIRCOUTCOMES.112.966986. Epub 2013 Mar 12.

3.

Do European people with type 1 diabetes consume a high atherogenic diet? 7-year follow-up of the EURODIAB Prospective Complications Study.

Soedamah-Muthu SS, Chaturvedi N, Fuller JH, Toeller M; EURODIAB Prospective Complications Study Group.

Eur J Nutr. 2013 Oct;52(7):1701-10. doi: 10.1007/s00394-012-0473-7. Epub 2012 Dec 7.

PMID:
23224030
4.

Unhealthy dietary patterns associated with inflammation and endothelial dysfunction in type 1 diabetes: the EURODIAB study.

van Bussel BC, Soedamah-Muthu SS, Henry RM, Schalkwijk CG, Ferreira I, Chaturvedi N, Toeller M, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group.

Nutr Metab Cardiovasc Dis. 2013 Aug;23(8):758-64. doi: 10.1016/j.numecd.2012.04.005. Epub 2012 Jul 12.

PMID:
22795869
5.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

6.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

7.

Dietary saturated fat and fibre and risk of cardiovascular disease and all-cause mortality among type 1 diabetic patients: the EURODIAB Prospective Complications Study.

Schoenaker DA, Toeller M, Chaturvedi N, Fuller JH, Soedamah-Muthu SS; EURODIAB Prospective Complications Study Group.

Diabetologia. 2012 Aug;55(8):2132-41. doi: 10.1007/s00125-012-2550-0. Epub 2012 Apr 12.

8.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
9.

Type 1 diabetes and measles, mumps and rubella childhood infections within the Italian Insulin-dependent Diabetes Registry.

Ramondetti F, Sacco S, Comelli M, Bruno G, Falorni A, Iannilli A, d'Annunzio G, Iafusco D, Songini M, Toni S, Cherubini V, Carle F; RIDI Study Group.

Diabet Med. 2012 Jun;29(6):761-6. doi: 10.1111/j.1464-5491.2011.03529.x.

PMID:
22133003
10.

Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study.

Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group.

Eur J Endocrinol. 2012 Feb;166(2):325-32. doi: 10.1530/EJE-11-0662. Epub 2011 Nov 29.

11.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.

Lancet. 2011 Dec 10;378(9808):2005-12. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.

PMID:
22119496
12.

Brief elevation of hepatic enzymes due to liver ischemia in anorexia nervosa.

Giordano F, Arnone S, Santeusanio F, Pampanelli S.

Eat Weight Disord. 2010 Dec;15(4):e294-7.

PMID:
21406954
13.

Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12.

PMID:
21225239
14.

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators.

N Engl J Med. 2010 Sep 2;363(10):905-17. doi: 10.1056/NEJMoa1003114.

15.

Age-period-cohort analysis of 1990-2003 incidence time trends of childhood diabetes in Italy: the RIDI study.

Bruno G, Maule M, Merletti F, Novelli G, Falorni A, Iannilli A, Iughetti L, Altobelli E, d'Annunzio G, Piffer S, Pozzilli P, Iafusco D, Songini M, Roncarolo F, Toni S, Carle F, Cherubini V; RIDI Study Group.

Diabetes. 2010 Sep;59(9):2281-7. doi: 10.2337/db10-0151. Epub 2010 Jun 21.

16.

Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up.

Bellastella G, Rotondi M, Pane E, Dello Iacovo A, Pirali B, Dalla Mora L, Falorni A, Sinisi AA, Bizzarro A, Colao A, Chiovato L, De Bellis A; Italian Autoimmune Hypophysitis Network Study.

J Clin Endocrinol Metab. 2010 Aug;95(8):3750-7. doi: 10.1210/jc.2010-0551. Epub 2010 May 25.

PMID:
20501686
17.

Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies.

Brozzetti A, Marzotti S, Tortoioli C, Bini V, Giordano R, Dotta F, Betterle C, De Bellis A, Arnaldi G, Toscano V, Arvat E, Bellastella A, Mantero F, Falorni A; Italian Addison Network.

Eur J Endocrinol. 2010 Feb;162(2):361-9. doi: 10.1530/EJE-09-0618. Epub 2009 Nov 2.

18.

Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif.

Moretti S, De Falco V, Tamburrino A, Barbi F, Tavano M, Avenia N, Santeusanio F, Santoro M, Macchiarulo A, Puxeddu E.

Biochim Biophys Acta. 2009 Nov;1793(11):1634-45. doi: 10.1016/j.bbamcr.2009.09.001. Epub 2009 Sep 6.

19.

Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine.

Brunetti P, Muggeo M, Cattin L, Arcangeli A, Pozzilli P, Provenzano V, Francesconi A, Calatola P, Santeusanio F.

Nutr Metab Cardiovasc Dis. 2010 Sep;20(7):519-26. doi: 10.1016/j.numecd.2009.05.007. Epub 2009 Aug 22.

PMID:
19703761
20.

Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles.

La Marca A, Marzotti S, Brozzetti A, Stabile G, Artenisio AC, Bini V, Giordano R, De Bellis A, Volpe A, Falorni A; Italian Addison Network.

J Clin Endocrinol Metab. 2009 Oct;94(10):3816-23. doi: 10.1210/jc.2009-0817. Epub 2009 Jul 21.

PMID:
19622621
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk